BSH 2022 | The recent FDA approval of cilta-cel and its impact on myeloma patients in the UK
In this video, Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the recent FDA approval of ciltacabtagene autoleucel (cilta-cel) for the treatment of multiple myeloma, and the beneficial impact that this will have for patients in the UK. Dr Ramasamy briefly discusses some results from the CARTITUDE-1 (NCT03548207) trial and the excitement around the possibility of cilta-cel being the first CAR-T therapy available for myeloma patients in the UK. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Transcript (edited for clarity)
Cilta-cel is a real game changer for our patients. Cilta-cel is a CAR-T cell therapy that’s recently been approved by FDA. We have a study, CARTITUDE study, which looked at cilta-cel in triple refractory patients with response rates north of 70 odd percent. And these responses are persistent after about 2 years of follow-up. So this is quite a game changing therapy for our patients.
In the UK, we have had CAR-T cell treatments available for leukemia patients and for diffuse large B-cell lymphoma patients...
Cilta-cel is a real game changer for our patients. Cilta-cel is a CAR-T cell therapy that’s recently been approved by FDA. We have a study, CARTITUDE study, which looked at cilta-cel in triple refractory patients with response rates north of 70 odd percent. And these responses are persistent after about 2 years of follow-up. So this is quite a game changing therapy for our patients.
In the UK, we have had CAR-T cell treatments available for leukemia patients and for diffuse large B-cell lymphoma patients. So currently, NHS England has just opened up many more hospitals for CAR-T cell therapy in anticipation of making CAR-T cell therapy available to myeloma patients. And we think cilta-cel could be the first of these therapies coming through and it’s currently under evaluation by NICE, so we are really excited that we could have the opportunity of giving cilta-cel in the UK, in the NHS for myeloma patients, maybe even within a year.
Read more...
